During the nine months ended September 30, 2025, the recovery in the global economy remained modest, as uncertainty over the future heightened due to developments relating to the U.S. tariff policies and geopolitical risks. In the United States, the decline following the rush demand caused by the tariff policies weighed on the economic expansion. In Europe, production activities slowed due to the decline following the rush demand, and the economy moved sideways. In China, prolonged sluggish domestic demand and a stagnant real estate market led to continued weakness in the economy. Meanwhile, in Japan, although production activities declined, mainly in the mobility market, excessively pessimistic views regarding the U.S. tariff policies receded, and the economy trended toward a moderate recovery.
Under these conditions, during the nine months ended September 30, 2025, product demand remained firm in the Industrial Materials and the Medical Technologies segments, and the company acquired in the contract design/development and manufacturing organization (CDMO) of over-the-counter (OTC) drugs during the current period has begun to contribute to earnings. On the other hand, in the Devices segment, product demand for tablets declined compared to the same period of the previous year, when demand grew due to new product launches. In addition to these demand trends, profitability was also pressured by upfront expenses associated with new products for mobility components in the Industrial Materials segment.
As a result, regarding the financial results for the nine months ended September 30, 2025, net sales were ¥145,270 million (a decrease of 2.1% as compared to the same period of the previous year), operating profit was ¥3,508 million (a decrease of 40.6% as compared to the same period of the previous year) and profit attributable to owners of parent was ¥505 million (a decrease of 88.2% as compared to the same period of the previous year).